Current treatment approaches to early childhood medulloblastoma

References

• Kaatsch P, Rickert CH, Kuhl J et al. Population-based epidemiologic data on brain tumors in German children. Cancer92, 3155–3164 (2001).
   PubMed Web of Science ®Google Scholar
• McNeil DE, Cote TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance epidemiology and end results. Med. Pediatr. Oncol.39, 190–194 (2002).
   PubMedGoogle Scholar
• Raffel C. Medulloblastoma: molecular genetics and animal models. Neoplasia6, 310–322 (2004).
   PubMedGoogle Scholar
• Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology93, 1351–1359 (1969).
   PubMed Web of Science ®Google Scholar
• Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J. Neurosurg.85, 56–65 (1996).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J. Clin. Oncol.17, 2127–2136 (1999).
   PubMed Web of Science ®Google Scholar
• Kuhl J, Muller HL, Berthold F et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT’88/’89. Klin. Padiatr.210, 227–233 (1998).
   PubMedGoogle Scholar
• Kortmann RD, Kuhl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ‘91. Int. J. Radiat. Oncol. Biol. Phys.46, 269–279 (2000).
   PubMed Web of Science ®Google Scholar
• Taylor RE, Bailey CC, Robinson K et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J. Clin. Oncol.21, 1581–1591 (2003).
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized Phase III study. J. Clin. Oncol.17, 832–845 (1999).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr. Neurosurg.39, 60–67 (2003).
   PubMedGoogle Scholar
• Kellie SJ. Chemotherapy of central nervous system tumours in infants. Childs Nerv. Syst.15, 592–612 (1999).
   PubMedGoogle Scholar
• Evans AE, Jenkin RD, Sposto R et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosurg.72, 572–582 (1990).
   PubMed Web of Science ®Google Scholar
• Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med. Pediatr. Oncol.28, 348–354 (1997).
   PubMedGoogle Scholar
• Hoppe-Hirsch E, Brunet L, Laroussinie F et al. Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv. Syst.11, 340–345 (1995).
   PubMed Web of Science ®Google Scholar
• Palmer SL, Goloubeva O, Reddick WE et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J. Clin. Oncol.19, 2302–2308 (2001).
   PubMed Web of Science ®Google Scholar
• Bouffet E, Bernard JL, Frappaz D et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int. J. Radiat. Oncol. Biol. Phys.24, 79–85 (1992).
   PubMedGoogle Scholar
• Hong TS, Mehta MP, Boyett JM et al. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a Phase III combined modality study. Pediatr. Blood Cancer45, 676–682 (2005).
   PubMedGoogle Scholar
• Bailey CC, Gnekow A, Wellek S et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med. Pediatr. Oncol.25, 166–178 (1995).
   PubMedGoogle Scholar
• Saran FH, Driever PH, Thilmann C et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Int. J. Radiat. Oncol. Biol. Phys.42, 959–967 (1998).
   PubMed Web of Science ®Google Scholar
• Attard-Montalto S, Plowman N, Breatnach F et al. Is there a danger in delaying radiotherapy in childhood medulloblastoma? Br. J. Radiol.66, 807–813 (1993).
   PubMed Web of Science ®Google Scholar
• Tarbell NJ, Loeffler JS, Silver B et al. The change in patterns of relapse in medulloblastoma. Cancer68, 1600–1604 (1991).
   PubMed Web of Science ®Google Scholar
• Kovnar EH, Kellie SJ, Horowitz ME et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a Phase II study. J. Clin. Oncol.8, 330–336 (1990).
   PubMed Web of Science ®Google Scholar
• Loeffler JS, Kretschmar CS, Sallan SE et al. Preradiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.15, 177–181 (1988).
   PubMed Web of Science ®Google Scholar
• Guruangan S, Dunkel IJ, Goldman S et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J. Clin. Oncol.16, 2486–2493 (1998).
   PubMed Web of Science ®Google Scholar
• Kalifa C, Valteau D, Pizer B et al. High-dose chemotherapy in childhood brain tumours. Childs Nerv. Syst.15, 498–505 (1999).
   PubMed Web of Science ®Google Scholar
• Levin VA, Patlak CS, Landahl HD. Heuristic modeling of drug delivery to malignant brain tumors. J. Pharmacokinet. Biopharm.8, 257–296 (1980).
   PubMedGoogle Scholar
• van Eys J, Chen T, Moore T et al. Adjuvant chemotherapy for medulloblastoma and ependymoma using i.v. vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group Study. Cancer Treat. Rep.65, 681–684 (1981).
   PubMedGoogle Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med.293, 161–166 (1975).
   PubMed Web of Science ®Google Scholar
• Bleyer WA, Poplack DG, Simon RM. “Concentration × time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood51, 835–842 (1978).
   PubMed Web of Science ®Google Scholar
• Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit. Rev. Oncol. Hematol.37, 227–236 (2001).
   PubMed Web of Science ®Google Scholar
• Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med. Pediatr. Oncol.6, 207–213 (1979).
   PubMedGoogle Scholar
• Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin. Pharmacokinet.44, 1–31 (2005).
   PubMed Web of Science ®Google Scholar
• Blaney SM, Balis FM, Berg S et al. Intrathecal mafosfamide: a preclinical pharmacology and Phase I trial. J. Clin. Oncol.23, 1555–1563 (2005).
   PubMed Web of Science ®Google Scholar
• Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status? J. Neuro-oncol.75, 279–285 (2005).
   PubMed Web of Science ®Google Scholar
• Warren KE, Packer RJ. Current approaches to CNS tumors in infants and very young children. Expert Rev. Neurother.4, 681–690 (2004).
   PubMedGoogle Scholar
• van Eys J, Cangir A, Coody D, Smith B. MOPP regimen as primary chemotherapy for brain tumors in infants. J. Neurooncol.3, 237–243 (1985).
   PubMed Web of Science ®Google Scholar
• Ater JL, van Eys J, Woo SY et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J. Neurooncol.32, 243–252 (1997).
   PubMed Web of Science ®Google Scholar
• Horowitz ME, Mulhern RK, Kun LE et al. Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer61, 428–434 (1988).
   PubMed Web of Science ®Google Scholar
• Geyer R, Levy M, Berger MS et al. Infants with medulloblastoma: a single institution review of survival. Neurosurgery29, 707–710 (1991).
   PubMedGoogle Scholar
• Lashford LS, Campbell RH, Gattamaneni HR et al. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch. Dis. Child74, 219–223 (1996).
   PubMed Web of Science ®Google Scholar
• Kretschmar CS, Tarbell NJ, Kupsky W et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J. Neurosurg.71, 820–825 (1989).
   PubMed Web of Science ®Google Scholar
• Gajjar A, Mulhern RK, Heideman RL et al. Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J. Clin. Oncol.12, 1212–1216 (1994).
   PubMedGoogle Scholar
• Geyer JR, Zeltzer PM, Boyett JM et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J. Clin. Oncol.12, 1607–1615 (1994).
   PubMed Web of Science ®Google Scholar
• Hartsell WF, Gajjar A, Heideman RL et al. Patterns of failure in children with medulloblastoma: effects of preirradiation chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.39, 15–24 (1997).
   PubMedGoogle Scholar
• Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med.328, 1725–1731 (1993).
   PubMed Web of Science ®Google Scholar
• Walter AW, Mulhern RK, Gajjar A et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children’s Research Hospital. J. Clin. Oncol.17, 3720–3728 (1999).
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-oncol.1, 152–161 (1999).
   PubMedGoogle Scholar
• White L, Kellie S, Gray E et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children’s Cancer Study Group (ANZCCSG). J. Pediatr. Hematol. Oncol.20, 125–130 (1998).
   PubMed Web of Science ®Google Scholar
• Geyer JR, Sposto R, Jennings M et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J. Clin. Oncol.23, 7621–7631 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhl J, Beck J, Bode U et al. Delayed radiation therapy after postoperative chemotherapy in children less than 3 years of age with medulloblastoma. Results of the trial HIT-SKK’87, and preliminara results of the pilot trial HIT-SKK’92. Med. Pediatr. Oncol.25, 250 (1995).
   Google Scholar
• Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med.352, 978–986 (2005).
   PubMed Web of Science ®Google Scholar
• Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J. Clin. Oncol.16, 210–221 (1998).
   PubMed Web of Science ®Google Scholar
• Chi SN, Gardner SL, Levy AS et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J. Clin. Oncol.22, 4881–4887 (2004).
   PubMed Web of Science ®Google Scholar
• Grill J, Sainte-Rose C, Jouvet A et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol.6, 573–580 (2005).
   PubMed Web of Science ®Google Scholar
• Grill J, Kieffer V, Kalifa C. Measuring the neuro-cognitive side-effects of irradiation in children with brain tumors. Pediatr. Blood Cancer42, 452–456 (2004).
   PubMedGoogle Scholar
• Silber JH, Radcliffe J, Peckham V et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J. Clin. Oncol.10, 1390–1396 (1992).
   PubMed Web of Science ®Google Scholar
• Duffner PK, Cohen ME, Thomas PR, Lansky SB. The long-term effects of cranial irradiation on the central nervous system. Cancer56, 1841–1846 (1985).
   PubMed Web of Science ®Google Scholar
• Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist10, 293–310 (2004).
   PubMed Web of Science ®Google Scholar
• Mulhern RK, Merchant TE, Gajjar A et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol.5, 399–408 (2004).
   PubMed Web of Science ®Google Scholar
• Fouladi M, Gilger E, Kocak M et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J. Clin. Oncol.23, 7152–7160 (2005).
   PubMed Web of Science ®Google Scholar
• Mabbott DJ, Spiegler BJ, Greenberg ML et al. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J. Clin. Oncol.23, 2256–2263 (2005).
   PubMed Web of Science ®Google Scholar
• Ris MD, Packer R, Goldwein J et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. J. Clin. Oncol.19, 3470–3476 (2001).
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Feldman H, Jamison C et al. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.60, 531–536 (2004).
   PubMed Web of Science ®Google Scholar
• Kieffer-Renaux V, Viguier D, Raquin MA et al. Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatr. Blood Cancer45, 814–819 (2005).
   PubMed Web of Science ®Google Scholar
• Merchant TE, Mulhern RK, Krasin MJ et al. Preliminary results from a Phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J. Clin. Oncol.22, 3156–3162 (2004).
   PubMed Web of Science ®Google Scholar
• Norrell H, Wilson C. Brain tumor chemotherapy with methotrexate given intrathecally. A new technique. JAMA201, 93–95 (1967).
   PubMedGoogle Scholar
• Rosen G, Ghavimi F, Nirenberg A et al. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat. Rep.61, 681–690 (1977).
   PubMedGoogle Scholar
• Allen JC, Walker R, Rosen G. Preradiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J. Clin. Oncol.6, 649–653 (1988).
   PubMedGoogle Scholar
• Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy49, 92–104 (2003).
   PubMed Web of Science ®Google Scholar
• Butler RW, Hill JM, Steinherz PG et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J. Clin. Oncol.12, 2621–2629 (1994).
   PubMed Web of Science ®Google Scholar
• Riva D, Giorgi C, Nichelli F et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology59, 48–53 (2002).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Chernik NL, Posner JB. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch. Neurol.28, 96–102 (1973).
   PubMedGoogle Scholar
• Haykin M, Gorman M, van Hoff J et al. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J. Neurooncol.76, 153–157 (2006).
   Web of Science ®Google Scholar
• Duffner PK, Krischer JP, Horowitz ME et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group Study. Ann. Neurol.44, 313–316 (1998).
   PubMedGoogle Scholar
• Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol. Appl. Neurobiol.28, 257–282 (2002).
   PubMed Web of Science ®Google Scholar
• Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol.61, 215–225 (2002).
   PubMed Web of Science ®Google Scholar
• Pietsch T, Taylor MD, Rutka JT. Molecular pathogenesis of childhood brain tumors. J. Neurooncol.70, 203–215 (2004).
   PubMedGoogle Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature415, 436–442 (2002).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Paris MK, Basso U. Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments? Expert Rev. Anticancer Ther.3, 615–620 (2003).
   PubMedGoogle Scholar